Phillip G. Febbo
Chief Scientific & Medical OfficerDr. Phillip G. Febbo, also known as Phil, M.D., serves as chief scientific officer and chief medical officer at Veracyte, Inc. since Ocotber 02, 2023. He serves as Independent Director at Varian Medical Systems, Inc. since August 16, 2019. Dr. Febbo Co-Founded Panel Intelligence, LLC (formerly MedPanel, Inc.) in 1999 and served as its Chief Managing Officer. He served as Senior Vice President and Chief Medical Officer of Illumina, Inc. since March 26, 2018 until August 7, 2023. Dr. Febbo serves on staff at Dana-Farber Cancer Institute. Dr. Febbo was Chief Medical Officer at Genomic Health Inc. since August 2013 until 2018. After many years as a physician scientist at leading Institutes throughout the country, Dr. Febbo joined Genomic Health as Chief Medical Officer in 2013. Immediately prior to Genomic Health, he was a Professor of Medicine and Urology at the University of California, San Francisco since 2010—until2013 where his laboratory focused on using genomics to understand the biology and clinical behavior of prostate cancer and his clinical practice focused on genitourinary oncology. While at UCSF, he was the Co-Leader of the Prostate Cancer Program at the UCSF Helen Diller Family Comprehensive Cancer Center and the Program Principal Investigator of the Translational Research Program for the Alliance for Clinical Trials in Oncology. In 2004, he moved to Duke University Medical Center’s Institute of Genome Sciences and Policy. In 2010, Dr. Febbo returned to UCSF. His laboratory was funded by the NIH, DOD, Damon Runyon Cancer Research Foundation and the Prostate Cancer Foundation. He has been a member of the American Society for Clinical Investigation since 2009. After his fellowship in Medical Oncology at the Dana Farber Cancer Institute, he was an Attending Physician in the Genitourinary Oncology Center at the Dana Farber Cancer Institute, Instructor at Harvard Medical School and a post-doctoral fellow in Dr. Todd Golub's laboratory at the Dana Farber Cancer Institute as well as the Whitehead Institute Center for Genomic Research of MIT (now the Broad Institute). He served on the board of directors of the American College of Medical Genetics and Genomics Foundation (2018—2019). Dr. Febbo is a board-certified internist and is an instructor at Harvard Medical School. Dr. Febbo holds Bachelor of Arts degree in Biology from Dartmouth College, received his M.D. degree at the University of California, San Francisco and completed Internal Medicine Residency at the Brigham and Women's Hospital in Boston, Massachusetts. He completed his Internal Medicine residency training at Brigham and Women's Hospital in Boston and completed his Oncology Fellowship at Dana-Farber Cancer Institute.
Positions
- Company NameVeracyte, Inc.Stock CodeVCYTPositionChief Scientific & Medical OfficerColleagues
- MAMarc A. StapleyCEO & Director
- RSRobert S. EpsteinIndependent Chair
- RCRebecca ChambersExecutive VP & CFO
- AMAnnie McGuireExecutive VP, General Counsel & Head of Market Access
- JLJohn LeiteGlobal Chief Commercial Officer
- EJEvan JonesIndependent Director
- KEKarin EasthamIndependent Director
- JHJens H. HolsteinIndependent Director
